The Biospecimen, Pathology and Genomics Core for the Yale Lung Cancer SPORE will serve as the nexus for all human biospecimen acquisition, processing and analysis for all SPORE-sponsored research as well as provide support for all non-human model system specimen molecular analytics not currently offered through Yale shared facilities. Tissue biopsy procurement will be coordinated with all interventionalists and surgeons as this occurs at the bedside or in the operating room with research tissues derived from extra passes of the biopsy needle after the diagnostic specimen has been collected or collection at the surgical pathology bench. The Biospecimen, Pathology and Genomics Core will work closely with Yale Pathology Tissue Services, the research tissue procurement service supported within the Department of Pathology (also directed by David Rimm) to obtain fresh resection specimens. Specifically the Biospecimen, Pathology and Genomics Core will: 1) coordinate the acquisition, processing, aliquoting, storage and distribution for all whole blood samples and their derivatives (e.g., plasma, serum, buffy coat) required for the described research in Projects 1-4 as well as the Developmental and Career Development Award Programs? approved projects; 2) coordinate the acquisition, handling, storage and distribution for all lung cancer tissue sample collection required for Projects 1-4, Developmental and Career Development Awards; 3) generate conditionally reprogrammed primary lung cancer cell lines from fresh tissue samples for use in Projects 1-3; and 4) conduct molecular pathology experiments including partial support of whole exome sequencing, RNA-Seq and Copy Number Variation analysis (Projects 2 and 3); quantitative microRNA in situ hybridization (Projects 1 and 2) and other molecular pathology support as needed during the term of the SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA196530-03
Application #
9325319
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Choe, Junho; Lin, Shuibin; Zhang, Wencai et al. (2018) mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature 561:556-560
Bade, Brett C; Hyer, J Madison; Bevill, Benjamin T et al. (2018) A Patient-Centered Activity Regimen Improves Participation in Physical Activity Interventions in Advanced-Stage Lung Cancer. Integr Cancer Ther 17:921-927
Fan, Pang-Dian; Narzisi, Giuseppe; Jayaprakash, Anitha D et al. (2018) YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci U S A 115:E6030-E6038
Tentori, Augusto M; Nagarajan, Maxwell B; Kim, Jae Jung et al. (2018) Quantitative and multiplex microRNA assays from unprocessed cells in isolated nanoliter well arrays. Lab Chip 18:2410-2424
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
O'Malley, Stephanie S; Zweben, Allen; Fucito, Lisa M et al. (2018) Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA Psychiatry 75:129-138
Bondeson, Daniel P; Smith, Blake E; Burslem, George M et al. (2018) Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Cell Chem Biol 25:78-87.e5
Wang, Jun; Sanmamed, Miguel F; Datar, Ila et al. (2018) Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell :
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40

Showing the most recent 10 out of 74 publications